KALV Archived Articles
KalVista Pharmaceuticals (KALV): Capitalizing on the Oral Advantage in the Hereditary Angioedema Market
Published on March 15, 2025
KalVista Pharmaceuticals (NASDAQ:KALV): From Clinical Trials to Regulatory Milestones, Positioning for Potential Oral HAE Therapy Launch
Published on November 27, 2024
KalVista Pharmaceuticals: A Promising Oral Therapy for Hereditary Angioedema
Published on September 24, 2024